Noninvasive Prenatal DNA Testing: The Vanguard of Genomic Medicine

Annual Review of Medicine

Volumn 68, Issue , 2017, Pages 459-472

  Hui, Lisa ^a,b,c   Bianchi, Diana W ^d,e  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d TUFTS MEDICAL CENTER   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell free DNA analysis; Copy number variants (CNVs); Noninvasive prenatal screening; Pregnancy; Sex chromosome aneuploidy

Indexed keywords

DNA; CELL FREE NUCLEIC ACID;

ARTICLE; CELL FREE SYSTEM; CHROMOSOME ABERRATION; DNA DETERMINATION; GENE NUMBER; HEALTH CARE; HUMAN; MATERNAL PLASMA; MEDICAL CARE; MICRODELETION; MICRODUPLICATION; NON INVASIVE PROCEDURE; PATIENT ATTITUDE; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; SEX CHROMOSOME ABERRATION; SOCIAL ACCEPTANCE; TRISOMY 21; ATTITUDE TO HEALTH; DATA MINING; DNA MUTATIONAL ANALYSIS; ETHICS; GENETIC SCREENING; GENOMICS; PATENT; PROCEDURES; SOCIAL CHANGE; TRENDS;

CELL-FREE NUCLEIC ACIDS; CHROMOSOME ABERRATIONS; DATA MINING; DNA MUTATIONAL ANALYSIS; GENETIC TESTING; GENOMICS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTELLECTUAL PROPERTY; PRENATAL DIAGNOSIS; SOCIAL CHANGE;

EID: 85010022085     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-072115-033220     Document Type: Article

References (84)

1. Wang L, Wheeler DA. 2014. Genomic sequencing for cancer diagnosis and therapy. Annu. Rev. Med. 65:33-48
2. Weeke P, Roden DM. 2014. Applied pharmacogenomics in cardiovascular medicine. Annu. Rev. Med. 65:81-94
3. Bianchi DW. 2012. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat. Med. 18:1041-51
4. Wong FC, Lo YM. 2016. Prenatal diagnosis innovation: genome sequencing of maternal plasma. Annu. Rev. Med. 67:419-32
5. ACOG Comm. Pract. Bull. 2007. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet. Gynecol. 109:217-27
6. UK NHS Fetal Anomaly Screening Programme. 2014. Screening for Down's syndrome: UK National Screening Committee policy recommendations, 2011-2014 model of best practice. http://anr-dpn. vjf. cnrs. fr/sites/default/files/NSCModel-of-Best-Practice-DS%20screening2011-2014Sept2011.pdf
7. Wald NJ, Rodeck C, Hackshaw AK, et al. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J. Med. Screen. 10:56-104
8. Malone FD, Canick JA, Ball RH, et al. 2005. First-trimester or second-trimester screening, or both, for Down's syndrome. N. Engl. J. Med. 353:2001-11
9. Hui L, Muggli E, Halliday J. 2015. Population-based trends in prenatal screening and diagnosis for aneuploidy: a retrospective analysis of 38 years of state-wide data. BJOG 123:90-97
10. Lo YM, Corbetta N, Chamberlain PF, et al. 1997. Presence of fetal DNA in maternal plasma and serum. Lancet 350:485-87
11. Alberry M, Maddocks D, Jones M, et al. 2007. Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenat. Diagn. 27:415-18
12. Canick JA, Palomaki GE, Kloza EM, et al. 2013. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat. Diagn. 33:667-74
13. Lui YY, Chik KW, Chiu RW, et al. 2002. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48:421-27
14. Vora NL, Johnson KL, Basu S, et al. 2012. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat. Diagn. 32:912-14
15. Taylor-Phillips S, Freeman K, Geppert J, et al. 2016. Accuracy of non-invasive prenatal testing using cellfree DNA for detection of Down, Edwards and Patau syndromes: a systematic review and metaanalysis. BMJ Open 6:e010002. doi:10. 1136/bmjopen-2015-010002
16. Mennuti MT, Cherry AM, Morrissette JJ, Dugoff L. 2013. Is it time to sound an alarm about false-positive cell-free DNA testing for fetal aneuploidy Am. J. Obstet. Gynecol. 209:415-19
17. Benn P, Borrell A, Chiu R, et al. 2015. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat. Diagn. 35:725-34
18. Comm. Genet. Soc. Matern.-Fetal Med. 2015.committee Opinion No. 640: cell-free DNA screening for fetal aneuploidy. Obstet. Gynecol. 126:e31-e37
19. Dar P, Curnow KJ, Gross SJ, et al. 2014. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am. J. Obstet. Gynecol. 211:527. e1-e17
20. Bianchi DW, Parker RL, Wentworth JW, et al. 2014. DNA sequencing versus standard prenatal aneuploidy screening. N. Engl. J. Med. 370:799-808
21. Fiorentino F, Bobo S, Pizzuti F, et al. 2016. The importance of determining the limit of detection of non-invasive prenatal testing methods. Prenat. Diagn. 36:304-11
22. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. 2015. Circulating cell free DNA testing: Are some test failures informative Prenat. Diagn. 35:289-93
23. Gil MM, Quezada MS, Bregant B, et al. 2013. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet. Gynecol. 42:34-40
24. Gil MM, Revello R, Poon LC, et al. 2016. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet. Gynecol. 47:45-52
25. Bianchi DW, Prosen T, Platt LD, et al. 2013. Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma. Obstet. Gynecol. 121:1057-62
26. Gil MM, Quezada MS, Revello R, et al. 2015. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet. Gynecol. 45:249-66
27. Bianchi DW, Parsa S, Bhatt S, et al. 2015. Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet. Gynecol. 125:375-82
28. Grati FR, Bajaj K, Malvestiti F, et al. 2015. The type of feto-placental aneuploidy detected by cfDNA testing may influence the choice of confirmatory diagnostic procedure. Prenat. Diagn. 35:994-98
29. Wang Y, Chen Y, Tian F, et al. 2014. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin. Chem. 60:251-59
30. Russell LM, Strike P, Browne CE, et al. 2007. X chromosome loss and ageing. Cytogenet. Genome Res. 116:181-85
31. Peters D, Chu T, Yatsenko SA, et al. 2011. Noninvasive prenatal diagnosis of a fetal microdeletion syndrome. N. Engl. J. Med. 365:1847-48
32. Jensen TJ, Dzakula Z, Deciu C, et al. 2012. Detection of microdeletion 22q11. 2 in a fetus by nextgeneration sequencing of maternal plasma. Clin. Chem. 58:1148-51
33. Srinivasan A, Bianchi DW, Huang H, et al. 2013. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am. J. Hum. Genet. 92:167-76
34. Yu SC, Jiang P, ChoyKW, et al. 2013. Noninvasive prenatalmolecular karyotyping frommaternal plasma. PLOS ONE 8:e60968. doi:10. 1371/journal. pone. 0060968
35. Chen S, Lau TK, Zhang C, et al. 2013. A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. Prenat. Diagn. 33:584-90
36. Wapner RJ, Babiarz JE, Levy B, et al. 2015. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am. J. Obstet. Gynecol. 212:332. e1-e9
37. Zhao C, Tynan J, Ehrich M, et al. 2015. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin. Chem. 61:608-16
38. Yin A-H, Peng C-F, Zhao X, et al. 2015. Noninvasive detection of fetal subchromosomal abnormalities by semiconductor sequencing of maternal plasma DNA. PNAS 112:14670-75
39. Lo KK, Karampetsou E, Boustred C, et al. 2016. Limited clinical utility of non-invasive prenatal testing for subchromosomal abnormalities. Am. J. Hum. Genet. 98:1-11
40. Wapner RJ, Martin CL, Levy B, et al. 2012. Chromosomal microarray versus karyotyping for prenatal diagnosis. N. Engl. J. Med. 367:2175-84
41. Norton ME, Jelliffe-Pawlowski LL, Currier RJ. 2014. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet. Gynecol. 124:979-86
42. Helgeson J, Wardrop J, Boomer T, et al. 2015. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. Prenat. Diagn. 35:999-1004
43. Gross SJ, Stosic M, McDonald-McGinn DM, et al. 2016. Clinical experience with single-nucleotide polymorphism-based non-invasive prenatal screening for 22q11. 2 deletion syndrome. Ultrasound Obstet. Gynecol. 47:177-83
44. Hui L. 2016. Cell-free DNA testing for 22q11. 2 deletion syndrome: appraising the viability, effectiveness and appropriateness of screening. Ultrasound Obstet. Gynecol. 47:137-41
45. Yaron Y, Jani J, Schmid M, et al. 2015. Current status of testing for microdeletion syndromes and rare autosomal trisomies using cell-free DNA technology. Obstet. Gynecol. 126:1095-99
46. American Congress of Obstetricians and Gynecologists. 2016. Practice BulletinNo. 162 summary: screening for fetal aneuploidy. Obstet. Gynecol. 127:979-81
47. Lefkowitz RB, Tynan JA, Liu T, et al. 2016. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. Am. J. Obstet. Gynecol. 215:227. e1-e. 16
48. Taglauer ES, Wilkins-Haug L, BianchiDW. 2014. Review: cell-free fetalDNAin thematernal circulation as an indication of placental health and disease. Placenta 35(Suppl. ):S64-S68
49. Kalousek DK, Vekemans M. 1996. Confined placental mosaicism. J. Med. Genet. 33:529-33
50. Curnow KJ, Wilkins-Haug L, Ryan A, et al. 2015. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. Am. J. Obstet. Gynecol. 212:79. e1-e9
51. Sachs A, Blanchard L, Buchanan A, et al. 2015. Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. Prenat. Diagn. 35:968-71
52. Bianchi DW. 2015. Pregnancy: prepare for unexpected prenatal test results. Nature 522:29-30
53. Snyder HL, Curnow KJ, Bhatt S, Bianchi DW. 2016. Follow-up of multiple aneuploidies and single monosomies detected by noninvasive prenatal testing: implications for management and counseling. Prenat. Diagn. 36:203-9
54. Snyder MW, Simmons LE, Kitzman JO, et al. 2015. Copy-number variation and false positive prenatal aneuploidy screening results. N. Engl. J. Med. 372:1639-45
55. Meschino WS, Miller K, Bedford HM. 2016. Incidental detection of familial APP duplication: an unusual reason for a false positive NIPT result of trisomy 21. Prenat. Diagn. 36:382-84
56. Schuring-BlomH, LichtenbeltK, van GalenK, et al. 2016. Maternal vitamin B12 deficiency and abnormal cell-free DNA results in pregnancy. Prenat. Diagn. 36:790-93
57. DharajiyaNG, Namba A, Horiuchi I, et al. 2015. Uterine leiomyoma confounding a noninvasive prenatal test result. Prenat. Diagn. 35:990-93
58. Osborne CM, Hardisty E, Devers P, et al. 2013. Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat. Diagn. 33:609-11
59. Vandenberghe P, Wlodarska I, Tousseyn T, et al. 2015. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2:e55-e65
60. Amant F, Verheecke M, Wlodarska I, et al. 2015. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 1:814-19
61. Bianchi DW, Chudova D, Sehnert AJ, et al. 2015. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 314(2):162-69
62. Chandrasekharan S, Minear MA, Hung A, Allyse MA. 2014. Noninvasive prenatal testing goes global. Sci. Transl. Med. 6:231fs15
63. Chitty L, Cameron L, Daley R, et al. 2015. RAPID non-invasive prenatal testing (NIPT) evaluation study: executive summary. http://legacy. screening. nhs. uk/policydb-download. phpdoc=551
64. EMGO Inst. Health Care Res. 2014. TRIDENT study: trial by Dutch laboratories for evaluation of non-invasive prenatal testing (NIPT). EMGO Inst. Health Care Res., Amsterdam. http://www. emgo. nl/research/quality-of-care/research-projects/1451/trident-study-trial-by-dutch-laboratories-forevaluation-of-non-invasive-prenatal-testing-nipt/background
65. Robson S, Hui L. 2015. National decline in invasive diagnostic procedures in association with combined first trimester and cell-free DNA-based aneuploidy screening. Aust. N. Z. J. Obstet. Gynaecol. 55:507-10
66. Larion S, Warsof SL, Romary L, et al. 2014. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures. Obstet. Gynecol. 123:1303-10
67. Platt LD, Janicki MB, Prosen T, et al. 2014. Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. Am. J. Obstet. Gynecol. 211:368. e1-e7
68. Williams J 3rd, Rad S, Beauchamp S, et al. 2015. Utilization of noninvasive prenatal testing: impact on referrals for diagnostic testing. Am. J. Obstet. Gynecol. 213:102. e1-e6
69. Tabor A, Vestergaard CH, Lidegaard O. 2009. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet. Gynecol. 34:19-24
70. Halliday JL, Lumley J, Sheffield LJ, et al. 1992. Importance of complete follow-up of spontaneous fetal loss after amniocentesis and chorion villus sampling. Lancet 340:886-90
71. Hui L, The S, McCarthy EA, Walker SP. 2015. Emerging issues in invasive prenatal diagnosis: safety and competency in the post-NIPT era. Aust. N. Z. J. Obstet. Gynaecol. 55:541-46
72. Hui L, Tabor A, Walker SP, Kilby MD. 2016. How to safeguard competency and training in invasive prenatal diagnosis: "The elephant in the room. " Ultrasound Obstet. Gynecol. 47:8-13
73. Warsof SL, Larion S, Abuhamad AZ. 2015. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat. Diagn. 35:972-79
74. Sago H, Sekizawa A, Japan NIPT Consortium. 2015. Nationwide demonstration project of nextgeneration sequencing of cell-free DNA in maternal plasma in Japan: 1-year experience. Prenat. Diagn. 35:331-36
75. Natoli JL, Ackerman DL, McDermott S, Edwards JG. 2012. Prenatal diagnosis of Down syndrome: a systematic review of termination rates (1995-2011). Prenat. Diagn. 32:142-53
76. Scior K, Addai-Davis J, Kenyon M, Sheridan JC. 2013. Stigma, public awareness about intellectual disability and attitudes to inclusion among different ethnic groups. J. Intellect. Disabil. Res. 57:1014-26
77. Halverson CM, Clift KE, McCormick JB. 2016. Was it worth it Patients' perspectives on the perceived value of genomic-based individualized medicine. J.community Genet. 7:145-52
78. Bernhardt BA, Soucier D, Hanson K, et al. 2013. Women's experiences receiving abnormal prenatal chromosomal microarray testing results. Genet. Med. 15:139-45
79. Dondorp W, de Wert G, Bombard Y, et al. 2015. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur. J. Hum. Genet. 23:1592
80. Hodgson J, Metcalfe S, GaffC, et al. 2016. Outcomes of a randomised controlled trial of a complex genetic counselling intervention to improve family communication. Eur. J. Hum. Genet. 24:356-60
81. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. 2015. Global perspectives on clinical adoption of NIPT. Prenat. Diagn. 35:959-67
82. Sun Y, Almasri E, Wu Y, et al. 2015. Characterization of common maternal copy number variations observed in non-invasive prenatal testing. Presented at Am. Soc. Hum. Genet. Annu. Meet., Baltimore, MD, Oct. 6-10
83. Xu H, Chen F, Jin X, et al. 2015. Chinese population allele frequency estimations based on large-scale non-invasive prenatal testing samples. Presented at Am. Soc. Hum. Genet. Annu. Meet., Baltimore, MD, Oct. 6-10
84. Edwards KL, Korngiebel DM, Pfeifer L, et al. 2016. Participant views on consent in cancer genetics research: preparing for the precision medicine era. J.community Genet. 7:133-43